Cytokine production in Linomide-treated NOD mice and the potential role of a Th1/Th2 shift on autoimmune and anti-inflammatory processes

被引:22
作者
Weiss, L
Barak, V
Zeira, M
Abdul-Hai, A
Raibstein, I
Reich, S
Hirschfeld, E
Gross, DJ
Slavin, S
机构
[1] Hadassah Univ Hosp, Dept Bone Marrow Transplantat, Canc Immunotherapy & Immunobiol Res Ctr, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Canc Immunotherapy, IL-91120 Jerusalem, Israel
[3] Hadassah Univ Hosp, Immunol Lab, Dept Oncol, IL-91120 Jerusalem, Israel
[4] Hadassah Univ Hosp, Dept Endocrinol & Metab, IL-91120 Jerusalem, Israel
关键词
Linomide; NOD (non-obese diabetic) mice; diabetes mellitus; autoimmune disease; Th1Th2; cytokines;
D O I
10.1006/cyto.2002.1956
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Linomide prevents the development of autoimmune insulitis; and insulin-deficient diabetes mellitus in female NOD mice. Linomide prevents development of autoimmune manifestations in other experimentally induced and spontaneous autoimmune diseases as well, but the mechanism of action is unknown. The present report summarizes our investigations on the effect of Linomide on different functional T cell subsets in NOD mice analyzed according to their cytokine profile. Supernatants from cultured splenocytes and peritoneal cells taken from Linomide-treated mice contained lower levels of TNFalpha, IL-1beta, IFNgamma and IL-12 versus higher levels of IL-4, IL-6 and IL-10 in comparison with supernatants from cultures of untreated mice. Our results suggest that regulation of autoimmunity following oral Linomide administration in NOD mice induces a shift from Th-1 to Th-2 phenotype response, thereby preventing the development of diabetes by active cytokine-induced immunoregulation of T cell subsets, including downregulation of Th-1 and upregulation of Th-2. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:85 / 93
页数:9
相关论文
共 43 条
[1]   The novel immunomodulator, linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors [J].
Condiotti, R ;
Slavin, S ;
Barak, V ;
Nagler, A .
LEUKEMIA RESEARCH, 1996, 20 (01) :57-63
[2]   Inhibition of autoimmune disease by the immunomodulator linomide correlates with the ability to activate macrophages [J].
Dahlén, E ;
Andersson, M ;
Dawe, K ;
Tellander, AC ;
Brunmark, C ;
Björk, A ;
Hedlund, G .
AUTOIMMUNITY, 2000, 32 (03) :199-211
[3]  
Dahlén E, 1998, J IMMUNOL, V160, P3585
[4]  
FLORENTINO DF, 1991, J IMMUNOL, V146, P3444
[5]  
GROSS DJ, 1994, DIABETOLOGIA, V37, P1195, DOI 10.1007/BF00399792
[6]   IMMUNE DISTURBANCE AND PATHOGENESIS OF NONOBESE DIABETES-PRONE (NOD) MICE [J].
HARADA, M .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY, 1987, 89 (03) :251-258
[7]   Linomide does not prevent spontaneous autoimmune thyroiditis in NOD mice [J].
Hartoft-Nielsen, ML ;
Rasmussen, ÅK ;
Kaas, A ;
Bock, T ;
Buschard, K ;
Feldt-Rasmussen, U .
AUTOIMMUNITY, 2001, 33 (02) :79-+
[8]   IN-VIVO ACTIVITY AND IN-VITRO SPECIFICITY OF CD4(+) TH1 AND TH2 CELLS DERIVED FROM THE SPLEENS OF DIABETIC NOD MICE [J].
HEALEY, D ;
OZEGBE, P ;
ARDEN, S ;
CHANDLER, P ;
HUTTON, J ;
COOKE, A .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 95 (06) :2979-2985
[9]   GENES ENCODING TUMOR NECROSIS FACTOR-ALPHA AND GRANZYME-A ARE EXPRESSED DURING DEVELOPMENT OF AUTOIMMUNE DIABETES [J].
HELD, W ;
MACDONALD, HR ;
WEISSMAN, IL ;
HESS, MW ;
MUELLER, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (06) :2239-2243
[10]  
Hortelano S, 1997, J IMMUNOL, V158, P1402